doi: 10.1002/fsn3.694 144
Promotional segments show that this weight loss medication is to be targeted towards individuals who are obese, overweight and have type 2 diabetes, sleep apnea, hypertension, knee osteoarthritis, cholesterol concerns, and/or dementia
Use of an alternative or additional non-oral contraceptive method is recommended for 4 weeks after initiating tirzepatide and for 4 weeks after each dose increase
At the same time, both Lilly and Novo Nordisk made multi-billion dollar capital investments in expanding their manufacturing capacity to satisfy unrelenting patient demand, including pharmas largest M&A deal of the year, the $16.5Bn acquisition of CDMO Catalent by Novo Holdings, the controlling shareholder of Novo Nordisk
The terms note that "medical consult fees are not subject to or eligible for a refund" if a prescription is not issued